Figure 5.

T181 is required for IRF1 to promote RNA Pol-II elongation on target promoters. (A) H3396 cells expressing Tet-inducible IRF1 WT or T181A were treated with vehicle or induced with Dox for 36 hr. ChIP was performed using anti-total RNA-Pol-II, or IgG antibodies (as control). QPCR was performed to detect enrichment at the TBC1D32 promoter region containing the IRF1 binding site. (B) ChIP performed as in A, but using anti-phospho-Ser² RNA Pol-II antibody and QPCR performed using primers from within the TBC1D32 gene body to detect the elongating form of RNA-Pol-II.